World Health Organization. Guidelines for the control of shigellosis including epidemics due to Shigella dysenteriae type 1. Geneva, Switzerland. 2005. http://apps.who.int/iris/bitstream/10665/43252/1/924159330X.pdf. Accessed 5 Nov 2014.
Lima AM, Lima NL, Pinho CNM, Barros EA, Teixeira MJ, Martins MC, Guerrant RL. High frequency of strains multiply resistant to ampicillin, trimethoprim–sulfamethoxazole, streptomycin, chloramphenicol, and tetracycline isolated from patients with shigellosis in Northeastern Brazil during the period 1988 to 1993. Antimicrob Agents Chemother. 1995;39:256–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Niyogi SK. Shigellosis. J Microbiol. 2005;43:133–43.
PubMed
Google Scholar
Von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, do Canh G, Chaicumpa W, Agtini MD, Hossain A, Bhutta ZA, Mason C, Sethabutr O, Talukder K, Nair GB, Deen JL, Kotloff K, Clemens JA. Multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Med. 2006. doi:10.1371/journal.pmed.0030353.
Google Scholar
Tajbakhsh M, García Migura L, Rahbar M, Svendsen CA, Mohammadzadeh M, Zali MR, Aarestrup FM, Hendriksen RS. Antimicrobial resistant Shigella infections from Iran: an overlooked problem? J Antimicrob Chemother. 2012;67:1128–33.
Article
CAS
PubMed
Google Scholar
Zhang W, Luo Y, Li J, Lin L, Ma Y, Hu C, Jin S, Ran L, Cui S. Wide dissemination of multidrug-resistant Shigella isolates in China. J Antimicrob Chemother. 2011;66:2527–35.
Article
CAS
PubMed
Google Scholar
Fortineau N, Naas T, Gaillot O, Nordmann P. SHV-type extended-spectrum β-lactamase in a Shigella flexneri clinical isolate. J Antimicrob Chemother. 2001;47:685–8.
Article
CAS
PubMed
Google Scholar
Pai H, Choi EH, Lee HJ, Hong JY, Jacoby GA. Identification of CTX-M-14 extended-spectrum β-lactamase in clinical isolates of Shigella sonnei, Escherichia coli and Klebsiella pneumonia in Korea. J Clin Microbiol. 2001;39:3747–9.
Article
CAS
PubMed
PubMed Central
Google Scholar
Radice M, González C, Power P, Vidal MC, Gutkind G, et al. Third-generation cephalosporin resistance in Shigella sonnei Argentina. Emerg Infect Dis. 2001;7:442–3.
Article
CAS
PubMed
PubMed Central
Google Scholar
Nguyen NT, Ha V, Tran NV, Stabler R, Pham DT, Le TM, van Doorn HR, Cerdeño-Tárraga A, Thomson N, Campbell J, Nguyen VM, Tran TT, Pham MV, Cao TT, Wren B, Farrar J, Baker S. The sudden dominance of blaCTX-M harbouring plasmids in Shigella spp. circulating in Southern Vietnam. PLoS Negl Trop Dis. 2010. doi:10.1371/journal.pntd.0000702.
Google Scholar
Acikgoz ZC, Gulay Z, Bicmen M, Gocer S, Gamberzade S. CTX-M-3 extended-spectrum β-lactamase in a Shigella sonnei clinical isolate: first report from Turkey. Scand J Infect Dis. 2003;35:503–5.
Article
CAS
PubMed
Google Scholar
Bhattacharya D, Bhattacharjee H, Ramanathan T, Sudharma SD, Singhania M, Sugunan AP, Roy S. Third generation cephalosporin resistance in clinical isolate of Shigella sonnei in Andaman & Nicobar Islands India. J Infect Dev Ctries. 2011;5:674–86.
CAS
PubMed
Google Scholar
Chander A, Shrestha CD. Prevalence of extended spectrum beta lactamase producing Escherichia coli and Klebsiella pneumoniae urinary isolates in a tertiary care hospital in Kathmandu, Nepal. BMC Res Notes. 2013;6:487.
Article
PubMed
PubMed Central
Google Scholar
Shrestha S, Amatya R, Dutta R. Prevalence of extended spectrum beta lactamase (ESBL) production in gram negative isolates from pyogenic infection in tertiary care hospital of Eastern Nepal. Nepal Med Coll J. 2011;13:186–9.
CAS
PubMed
Google Scholar
Mishra KS, Kattel H, Pokhrel BM. High prevalence of extended-spectrum-beta-lactamase- producing respiratory bacterial pathogens in a Nepalese University Hospital: a vexatious problem. ACCLM. 2015;1:8–14.
Google Scholar
Paterson DL, Bonomo RA. Extended-spectrum beta-lactamase: a clinical update. Clin Microbiol Rev. 2005;18:657–86.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rupp ME, Fey PD. Extended spectrum β-lactamase (ESBL)—producing enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drug. 2003;63:353–65.
Article
CAS
Google Scholar
Henry DI. Clinical microbiology procedures handbook. 2nd ed. Washington, DC: ASM Press; 2004.
Google Scholar
Sharon ME, Elizabeth EB, Janet FH. Options for treating resistant Shigella species infections in children. J Pediatr Pharmacol Ther. 2008;13:29–43.
Google Scholar
Clinical and Laboratory Standards Insitute. Performance standards for antimicrobial susceptebility testing: nineteenth informational supplement M100-S19. Wayne: CLSI; 2009.
Google Scholar
Shah BK, Sharma S, Shakya G, Upadhyay BP. Multidrug resistant Vibrio cholera, Salmonella and Shigella from Nepalgunj cholera outbreak and different hospitals of Nepal. Nepal J Biosci. 2012;2:31–9.
Google Scholar
Bhattacharya S, Khanal B, Bhattarai NR, Das ML, et al. Prevalence of Shigella species and their antimicrobial resistance pattern in Eastern Nepal. J Health Popul Nutr. 2005;23:339–42.
PubMed
Google Scholar
Kansakar P, Malla S, Ghimire GR. Shigella isolates of Nepal: changes in incidence of Shigella subgroups and trends of antimicrobial susceptibility pattern. KUMJ. 2007;5:32–7.
CAS
PubMed
Google Scholar
Taneja N. Changing epidemiology of shigellosis and emergence of ciprofloxacin-resistant Shigella in India. J Clin Microbiol. 2007;45:678–9.
Article
PubMed
Google Scholar
Rahman M, Shoma S, Rashid H, Siddique AK, Nair GB, Sack DA. Extended spectrum beta-lactamase mediated third generation cephalosporin resistance in Shigella isolates in Bangladesh. J Antimicrob Chemother. 2004;54:846–7.
Article
CAS
PubMed
Google Scholar